StageZero Financial Statements From 2010 to 2025
| SZLSF Stock | USD 0.0005 0 90.20% |
Check StageZero Life financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among StageZero Life's main balance sheet or income statement drivers, such as , as well as many indicators such as . StageZero financial statements analysis is a perfect complement when working with StageZero Life Valuation or Volatility modules.
StageZero |
StageZero Life Sciences Company Return On Equity Analysis
StageZero Life's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current StageZero Life Return On Equity | -1.69 |
Most of StageZero Life's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, StageZero Life Sciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, StageZero Life Sciences has a Return On Equity of -1.6885. This is 92.96% lower than that of the Healthcare sector and 74.72% lower than that of the Diagnostics & Research industry. The return on equity for all United States stocks is notably higher than that of the company.
StageZero Life Sciences Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining StageZero Life's current stock value. Our valuation model uses many indicators to compare StageZero Life value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across StageZero Life competition to find correlations between indicators driving StageZero Life's intrinsic value. More Info.StageZero Life Sciences is rated fifth in return on equity category among its peers. It is currently regarded as top stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the StageZero Life's earnings, one of the primary drivers of an investment's value.About StageZero Life Financial Statements
StageZero Life stakeholders use historical fundamental indicators, such as StageZero Life's revenue or net income, to determine how well the company is positioned to perform in the future. Although StageZero Life investors may analyze each financial statement separately, they are all interrelated. For example, changes in StageZero Life's assets and liabilities are reflected in the revenues and expenses on StageZero Life's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in StageZero Life Sciences. Please read more on our technical analysis and fundamental analysis pages.
StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in the United States and Canada. The company was founded in 1998 and is headquartered in Richmond Hill, Canada. Stagezero Life operates under Diagnostics Research classification in the United States and is traded on OTC Exchange. It employs 80 people.
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Other Information on Investing in StageZero Pink Sheet
StageZero Life financial ratios help investors to determine whether StageZero Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in StageZero with respect to the benefits of owning StageZero Life security.